Overview

Study of Neoadjuvant Checkpoint Blockade in Patients With Surgically Resectable Undifferentiated Pleomorphic Sarcoma and Dedifferentiated Liposarcoma

Status:
Recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if giving nivolumab alone or in combination with ipilimumab before standard of care surgery can help to control sarcoma. The safety of these drugs will also be studied. This is an investigational study. Ipilimumab and nivolumab are FDA approved and commercially available to treat melanoma, lung cancer, and renal cell cancer. It is considered investigational to use these drugs to treat sarcoma. The study doctor can explain how the study drugs are designed to work. Up to 40 participants will be enrolled in this study. All will take part at MD Anderson.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Bristol-Myers Squibb

Treatments:

Antibodies, Monoclonal
Nivolumab